prmt5

MRTX-1719 is a potent and selective inhibitor of the PRMT5 MTA complex with an IC50 value of <10 nM against PRMT5 MTAMTAPDELSDMA cell lines.

CMP-5 is a PRMT5 inhibitor with antiviral activity, inhibits PRMT5 methyltransferase activity, and can be used in the study of SARS virus infection.

(Iso)-MS4322 ((Iso)-YS43-22) is a selective and potent protein arginine methyltransferase 5 (PRMT5) degrader with potential anticancer activity that effectively reduces PRMT5 protein levels in MCF-7 cells and inhibits the growth of a wide range of cancer cells.

AGI-24512 is a potent inhibitor of methionine adenylyltransferase 2α (MAT2A) (IC50: 8 nM).AGI-24512 shows antiproliferative activity in MTAP-deficient cancer cells.AGI-24512 inhibits MAT2A, which causes DNA damage in MTAP, and is often used in conjunction with anticancer compounds in cancer research.

JNJ-64619178 is a selective, orally active, and pseudo-irreversible inhibitor of protein arginine methyltransferase 5 (IC50: 0.14 nM). It has effective activity In lung cancer.

PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5 MEP50).

PRMT5-IN-2 is an inhibitor of protein arginine methyltransferase 5.

PRMT5-IN-45 (compound 36) is a potent and selective inhibitor of PRMT5, exhibiting an IC50 value of 3 nM. This compound effectively reduces the levels of symmetrical dimethylarginine (sDMA) and inhibits the proliferation of the MOLM-13 cell line by inducing apoptosis and causing cell cycle arrest.

PRMT5-MTA-IN-2 (compound 1) is a synergistic inhibitor of PRMT5 with an IC50 of less than 1.5 nM.

PRMT5-IN-49 (Compound 4b16) is an inhibitor of PRMT5.

PRMT5-IN-47 (compound 20) is a potent, selective, and orally active MTA co-operative PRMT5 inhibitor, with an IC50 value of 15 nM. It exhibits antiproliferative and anticancer activity.

PRMT5-IN-46 (compound 278) inhibits PRMT5 with an IC50 range of 1.001-10.000 μM. PRMT5 is a methyltransferase associated with specific genetic alterations. PRMT5-IN-46 is applicable in the study of proliferative diseases, metabolic disorders, and hematological conditions.

PRMT5ligand 1 is a ligand of PRMT5, used as a target protein ligand in the synthesis of the PROTAC degrader MS4322.

PRMT5-IN-48 (compound D3) is an orally active PRMT5 inhibitor with an IC50 of 20.7 nM, displaying antitumor activity. It effectively suppresses the growth of various cancer cells, induces apoptosis, and causes cell cycle arrest at the G0 G1 phase. PRMT5-IN-48 is applicable for research in non-Hodgkin's lymphoma (NHL).

PRMT5-IN-4 (compound AAA-1) is a PRMT5 inhibitor. This chemical compound specifically impedes the activity of PRMT5, an enzyme involved in the methylation of arginine residues on target proteins, which plays a critical role in various cellular processes.

PRMT5-IN-14 is a PRMT5 inhibitor used to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

PRMT5-IN-13 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5).

PRMT5-IN-15, a PRMT5 inhibitor, has an IC50 value of 0.84 nM.

PRMT5-IN-11 demonstrates potent structure-dependent inhibition against the protein methyltransferase PRMT5:MEP50 complex at submicromolar concentrations.

PRMT5-IN-12 demonstrates significant inhibitory activity on PRMT5.

PRMT5-IN-9 is a novel PRMT5 inhibitor for treating cancer, with an IC50 of 0.01 μM.

PRMT5-IN-10 exhibits promising structure-dependent inhibitory effect on the protein methyltransferase PRMT5:MEP50 complex.

PRMT5-IN-19 (Compound 41) is a potent, orally active PRMT5 inhibitor, exhibiting selectivity towards the SAM-binding pocket of PRMT5 with IC50 values of 23.9 nM (radioactive biochemical assay) and 47 nM (AlphaLISA assay). It effectively blocks methyltransferase activity and demonstrates high specificity against other PRMTs and PKMTs, exerting anti-proliferative effects through apoptosis induction and holding potential in cancer-related research [1].

PRMT5-IN-21 (compound 1) is a potent inhibitor of the cyclonucleoside enzyme PRMT5.